HLA-G expression in melanomas

References

• Kovats S, Main EK, Librach C, et al. A. class I antigen, HLA-G, expressed in human trophoblasts. Science. 1990;248(4952):220–223. doi:10.1126/science.2326636.
   PubMed Web of Science ®Google Scholar
• Lin A, Yan WH. Heterogeneity of HLA-G expression in cancers: facing the challenges. Front Immunol. 2018;9:2164 doi:10.3389/fimmu.2018.02164.
   PubMed Web of Science ®Google Scholar
• Dahl M, Hviid TVF. Human leucocyte antigen class Ib molecules in pregnancy success and early pregnancy loss. Hum Reprod Update. 2012;18(1):92–109. doi:10.1093/humupd/dmr043.
   PubMed Web of Science ®Google Scholar
• Ferreira LMR, Meissner TB, Tilburgs T, et al. HLA-G: At the interface of maternal-fetal tolerance. Trends Immunol. 2017;38(4):272–286. doi:10.1016/j.it.2017.01.009.
   PubMed Web of Science ®Google Scholar
• Le Gal FA, Riteau B, Sedlik C, et al. HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes. Int Immunol. 1999;11(8):1351–1356. doi:10.1093/intimm/11.8.1351.
   PubMed Web of Science ®Google Scholar
• Selmani Z, Naji A, Zidi I, et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4 + CD25highFOXP3+ regulatory T cells. Stem Cells. 2008;26(1):212–222. doi:10.1634/stemcells.2007-0554.
   PubMed Web of Science ®Google Scholar
• González A, Rebmann V, LeMaoult J, et al. The immunosuppressive molecule HLA-G and its clinical implications. Crit Rev Clin Lab Sci. 2012;49(3):63–84. doi:10.3109/10408363.2012.677947.
   PubMed Web of Science ®Google Scholar
• da Silva GBRF, Silva TGA, Duarte RA, et al. Expression of the classical and nonclassical HLA molecules in breast cancer. Int J Breast Cancer. 2013;2013:250435). doi:10.1155/2013/250435.
   PubMedGoogle Scholar
• Ye S-R, Yang H, Li K, et al. Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol. 2007;20(3):375–383. doi:10.1038/modpathol.3800751.
   PubMed Web of Science ®Google Scholar
• Yie S-M, Yang H, Ye S-R, et al. Expression of HLA-G is associated with prognosis in esophageal squamous cell carcinoma. Am J Clin Pathol. 2007;128(6):1002–1009. doi:10.1309/JNCW1QLDFB6AM9WE.
   PubMed Web of Science ®Google Scholar
• Du L, Xiao X, Wang C, et al. Human leukocyte antigen-G is closely associated with tumor immune escape in gastric cancer by increasing local regulatory T cells. Cancer Sci. 2011;102(7):1272–1280. doi:10.1111/j.1349-7006.2011.01951.x.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ye Z, Meng X-Q, et al. Expression of HLA-G in patients with hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 2011;10(2):158–163. doi:10.1016/S1499-3872(11)60025-8.
   PubMed Web of Science ®Google Scholar
• Li X-J, Zhang X, Lin A, et al. Human leukocyte antigen-G (HLA-G) expression in cervical cancer lesions is associated with disease progression. Hum Immunol. 2012;73(9):946–949. doi:10.1016/j.humimm.2012.07.041.
   PubMed Web of Science ®Google Scholar
• Bijen CBM, Bantema-Joppe EJ, de Jong RA, et al. The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer. Int J Cancer. 2010;126(6):1417–1427. doi:10.1002/ijc.24852.
   PubMed Web of Science ®Google Scholar
• Menier C, Prevot S, Carosella ED, et al. Human leukocyte antigen-G is expressed in advanced-stage ovarian carcinoma of high-grade histology. Hum Immunol. 2009;70(12):1006–1009. doi:10.1016/j.humimm.2009.07.021.
   PubMed Web of Science ®Google Scholar
• Wastowski IJ, Simões RT, Yaghi L, et al. Human leukocyte antigen-G is frequently expressed in glioblastoma and may be induced in vitro by combined 5-aza-2'-deoxycytidine and interferon-γ treatments: results from a multicentric study . Am J Pathol. 2013;182(2):540–552. doi:10.1016/j.ajpath.2012.10.021.
   PubMed Web of Science ®Google Scholar
• Spurny C, Kailayangiri S, Altvater B, et al. T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G. Oncotarget. 2018;9(5):6536–6549. doi:10.18632/oncotarget.23815.
   PubMedGoogle Scholar
• Caocci G, Greco M, Fanni D, et al. G, HLA-G expression and role in advanced-stage classical Hodgkin lymphoma. Eur J Histochem. 2016;60(2):2606 doi:10.4081/ejh.2016.2606.
   PubMed Web of Science ®Google Scholar
• Sukari A, Nagasaka M, Al-Hadidi A, et al. Cancer Immunology and Immunotherapy. Anticancer Res. 2016;36(11):5593–5606. doi:10.21873/anticanres.11144.
   PubMed Web of Science ®Google Scholar
• Rodig SJ, Gusenleitner D, Jackson DG, et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci Transl Med. 2018;10(450):eaar3342. doi:10.1126/scitranslmed.aar3342.
   PubMed Web of Science ®Google Scholar
• Ruiter DJ, Bergman W, Welvaart K, et al. Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. Cancer Res. 1984;44(9):3930–3935.
   PubMed Web of Science ®Google Scholar
• Bröcker EB, Suter L, Brüggen J, et al. Phenotypic dynamics of tumor progression in human malignant melanoma. Int J Cancer. 1985;36(1):29–35. doi:10.1002/ijc.2910360106.
   PubMed Web of Science ®Google Scholar
• Ruiter DJ, Mattijssen V, Broecker EB, Ferrone S. MHC antigens in human melanomas. Semin Cancer Biol. 1991;2(1):35–45.
   PubMedGoogle Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700 doi:10.1136/bmj.b2700.
   PubMed Web of Science ®Google Scholar
• Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–2012. doi:10.1001/jama.283.15.2008.
   PubMed Web of Science ®Google Scholar
• Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210 doi:10.1186/s13643-016-0384-4.
   PubMedGoogle Scholar
• Munn Z, Barker TH, Moola S, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020;18(10):2127–2133. doi:10.11124/JBISRIR-D-19-00099.
   PubMedGoogle Scholar
• Paul P, Rouas-Freiss N, Khalil-Daher I, et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A. 1998;95(8):4510–4515. doi:10.1073/pnas.95.8.4510.
   PubMed Web of Science ®Google Scholar
• Paul P, Cabestré FA, Le Gal FA, et al. Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Cancer Res. 1999;59(8):1954–1960.,
   PubMed Web of Science ®Google Scholar
• Rebmann V, Wagner S, Grosse-Wilde H. HLA-G expression in malignant melanoma. Semin Cancer Biol. 2007;17(6):422–429. doi:10.1016/j.semcancer.2007.06.010.
   PubMed Web of Science ®Google Scholar
• Bezuhly M, Howlett A, Colp P, et al. Quantitative HLA-G expression in metastasising and non-metastasising primary thin cutaneous melanomas. Dermatology. 2008;217(3):281–283. doi:10.1159/000150602.
   PubMed Web of Science ®Google Scholar
• Fang X, Zhang X, Li J. Up-regulation of human leukocyte antigen G expression in primary cutaneous malignant melanoma associated with host-vs-tumor immune response. J Huazhong Univ Sci Technolog Med Sci. 2008;28(2):219–221. doi:10.1007/s11596-008-0227-1.
   PubMedGoogle Scholar
• Castillo MZ, Pereira NV, Guedes F, et al. Overexpression of Human Leukocyte Antigen-G and Interleukin 10 in acral lentiginous melanoma. J Dermatol Sci. 2017;88(1):149–152. doi:10.1016/j.jdermsci.2017.05.014.
   PubMed Web of Science ®Google Scholar
• Melsted WN, Johansen LL, Lock-Andersen J, et al. HLA class Ia and Ib molecules and FOXP3+ TILs in relation to the prognosis of malignant melanoma patients. Clin. Immunol. 2017;183:191–197. doi:10.1016/j.clim.2017.09.004.
   PubMed Web of Science ®Google Scholar
• van Weeghel C, Wierenga APA, Versluis M, et al. Do GNAQ and GNA11 Differentially Affect Inflammation and HLA Expression in Uveal Melanoma? Cancers (Basel). 2019;11(8):1127. doi:10.3390/cancers11081127.
   Web of Science ®Google Scholar
• Real LM, Cabrera T, Collado A, et al. Expression of HLA G in human tumors is not a frequent event. Int J Cancer. 1999;81(4):512–518. doi:10.1002/(SICI)1097-0215(19990517)81:4<512::AID-IJC2>3.0.CO;2-O.
   PubMed Web of Science ®Google Scholar
• Frumento G, Franchello S, Palmisano GL, et al. Melanomas and melanoma cell lines do not express HLA-G, and the expression cannot be induced by gammaIFN treatment. Tissue Antigens. 2000;56(1):30–37. doi:10.1034/j.1399-0039.2000.560104.x.
   PubMed Web of Science ®Google Scholar
• Wagner SN, Rebmann V, Willers CP, et al. Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma. Lancet (London, England. 2000;356(9225):220–221. doi:10.1016/S0140-6736(00)02486-7.
   PubMed Web of Science ®Google Scholar
• Ugurel S, Rebmann V, Ferrone S, et al. Soluble human leukocyte antigen–G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer. 2001;92(2):369–376. doi:10.1002/1097-0142(20010715)92:2<369::AID-CNCR1332>3.0.CO;2-U.
   PubMed Web of Science ®Google Scholar
• Hurks HM, Valter MM, Wilson L, et al. Uveal melanoma: no expression of HLA-G. Invest Ophthalmol Vis Sci. 2001;42(13):3081–3084.
   PubMed Web of Science ®Google Scholar
• Davies B, Hiby S, Gardner L, et al. HLA-G expression by tumors. Am J Reprod Immunol. 2001;45(2):103–107. doi:10.1111/j.8755-8920.2001.450207.x.
   PubMed Web of Science ®Google Scholar
• Anastassiou G, Rebmann V, Wagner S, et al. Expression of classic and nonclassic HLA class I antigens in uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44(5):2016–2019. doi:10.1167/iovs.02-0810.
   PubMed Web of Science ®Google Scholar
• Ibrahim EC, Aractingi S, Allory Y, et al. Analysis of HLA antigen expression in benign and malignant melanocytic lesions reveals that upregulation of HLA-G expression correlates with malignant transformation, high inflammatory infiltration and HLA-A1 genotype. Int J Cancer. 2004;108(2):243–250. doi:10.1002/ijc.11456.
   PubMed Web of Science ®Google Scholar
• Yu Y, Wang Y, Feng M. Human leukocyte antigen-G1 inhibits natural killer cytotoxicity through blocking the activating signal transduction pathway and formation of activating immunologic synapse. Hum Immunol. 2008;69(1):16–23. doi:10.1016/j.humimm.2007.11.005.
   PubMed Web of Science ®Google Scholar
• Ketroussi F, Giuliani M, Bahri R, et al. Lymphocyte cell-cycle inhibition by HLA-G is mediated by phosphatase SHP-2 and acts on the mTOR pathway. PLoS One. 2011;6(8):e22776 doi:10.1371/journal.pone.0022776.
   PubMed Web of Science ®Google Scholar
• Lin A, Yan W-H, Xu H-H, et al. HLA-G expression in human ovarian carcinoma counteracts NK cell function. Ann Oncol Off J Eur Soc Med Oncol. 2007;18(11):1804–1809. doi:10.1093/annonc/mdm356.
   PubMed Web of Science ®Google Scholar
• Wiendl H, Mitsdoerffer M, Hofmeister V, et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol. 2002;168(9):4772–4780. doi:10.4049/jimmunol.168.9.4772.
   PubMed Web of Science ®Google Scholar
• Carosella ED, Gregori S, Rouas-Freiss N, et al. The role of HLA-G in immunity and hematopoiesis. Cell Mol Life Sci. 2011;68(3):353–368. doi:10.1007/s00018-010-0579-0.
   PubMed Web of Science ®Google Scholar
• Moretta A, Bottino C, Vitale M, et al. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol. 1996;14:619–648. doi:10.1146/annurev.immunol.14.1.619.
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565–1570. doi:10.1126/science.1203486.
   PubMed Web of Science ®Google Scholar
• Johansen LL, Lock-Andersen J, Hviid TVF. The Pathophysiological Impact of HLA Class Ia and HLA-G Expression and Regulatory T Cells in Malignant Melanoma: A Review. J Immunol Res. 2016;2016:6829283. 2016, ). doi:10.1155/2016/6829283.
   PubMed Web of Science ®Google Scholar
• Chae YK, Arya A, Iams W, et al. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018;6(1):39 doi:10.1186/s40425-018-0349-3.
   PubMed Web of Science ®Google Scholar
• Onitilo AA, Wittig JA. Principles of Immunotherapy in Melanoma. Surg Clin North Am. 2020;100(1):161–173. doi:10.1016/j.suc.2019.09.009.
   PubMed Web of Science ®Google Scholar
• Chowdhury PS, Chamoto K, Honjo T. Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy. J Intern Med. 2018;283(2):110–120. doi:10.1111/joim.12708.
   PubMed Web of Science ®Google Scholar
• Patel SA, Minn AJ. Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. Immunity. 2018;48(3):417–433. doi:10.1016/j.immuni.2018.03.007.
   PubMed Web of Science ®Google Scholar
• Carretero R, Romero JM, Ruiz-Cabello F, et al. Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics. 2008;60(8):439–447. doi:10.1007/s00251-008-0303-5.
   PubMed Web of Science ®Google Scholar
• Chang C, Murphy SP, Ferrone S. Differential In Vivo and In Vitro HLA-G Expression in Melanoma Cells: Potential Mechanisms. 2003;64(11):1057–1063. doi:10.1016/j.humimm.2003.08.357
   Google Scholar
• Rouas-Freiss N, Bruel S, Menier C, et al. Switch of HLA-G alternative splicing in a melanoma cell line causes loss of HLA-G1 expression and sensitivity to NK lysis. Int J Cancer. 2005;117(1):114–122. doi:10.1002/ijc.21151.
   PubMed Web of Science ®Google Scholar
• Pangault C, Amiot L, Caulet-Maugendre S, et al. HLA-G protein expression is not induced during malignant transformation. Tissue Antigens. 1999;53(4 Pt 1):335–346. doi:10.1034/j.1399-0039.1999.530403.x.
   PubMed Web of Science ®Google Scholar
• Apps R, Gardner L, Moffett A. A critical look at HLA-G. Trends Immunol. 2008;29(7):313–321. doi:10.1016/j.it.2008.02.012.
   PubMed Web of Science ®Google Scholar
• Swets M, Wouters A, Krijgsman D, et al. HLA-G protein expression in colorectal cancer evaluated by immunohistochemistry and western blot analysis: Its expression characteristics remain enigmatic. Clin Immunol. 2018;194:80–86. doi:10.1016/j.clim.2018.07.005.
   PubMed Web of Science ®Google Scholar
• Lin A, Chen H-X, Zhu C-C, et al. Aberrant human leucocyte antigen-G expression and its clinical relevance in hepatocellular carcinoma. J Cell Mol Med. 2010;14(8):2162–2171. doi:10.1111/j.1582-4934.2009.00917.x.
   PubMed Web of Science ®Google Scholar
• Vacca P, Pietra G, Tumino N, et al. Exploiting Human NK Cells in Tumor Therapy. Front Immunol. 2019;10:3013 doi:10.3389/fimmu.2019.03013.
   PubMedGoogle Scholar
• Cortés-Hernández A, Alvarez-Salazar EK, Soldevila G. Chimeric Antigen Receptor (CAR) T Cell Therapy for Cancer. Challenges and Opportunities: An Overview. Methods Mol Biol. 2021;2174:219–244. doi:10.1007/978-1-0716-0759-6_14.
   PubMedGoogle Scholar
• Wang Z, Wu Z, Liu Y, et al. New development in CAR-T cell therapy. J Hematol Oncol. 2017;10(1):53 doi:10.1186/s13045-017-0423-1.
   PubMedGoogle Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–1517. doi:10.1056/NEJMoa1407222.
   PubMed Web of Science ®Google Scholar
• Kalos M, Levine BL, Porter DL, et al. T. cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73 doi:10.1126/scitranslmed.3002842.
   PubMed Web of Science ®Google Scholar
• Massa C, Seliger B. The tumor microenvironment: Thousand obstacles for effector T cells. Cell Immunol. 2019;343:103730 doi:10.1016/j.cellimm.2017.12.004.
   PubMed Web of Science ®Google Scholar
• Simon B, Uslu U. CAR-T cell therapy in melanoma: A future success story? Exp Dermatol. 2018;27(12):1315–1321. doi:10.1111/exd.13792.
   PubMed Web of Science ®Google Scholar
• Kailayangiri S, Altvater B, Spurny C, et al. Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G. Oncoimmunology. 2017;6(1):e1250050. doi:10.1080/2162402X.2016.1250050.
   PubMed Web of Science ®Google Scholar
• Blom DJ, Luyten GP, Mooy C, et al. Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma. Invest Ophthalmol Vis Sci. 1997;38(9):1865–1872.
   PubMed Web of Science ®Google Scholar
• Blom DJ, Schurmans LR, De Waard-Siebinga I, et al. HLA expression in a primary uveal melanoma, its cell line, and four of its metastases. Br J Ophthalmol. 1997;81(11):989–993. doi:10.1136/bjo.81.11.989.
   PubMed Web of Science ®Google Scholar
• Zierhut M, Streilein JW, Schreiber H, et al. Immunology of ocular tumours. Immunol Today. 1999;20(11):482–485. doi:10.1016/S0167-5699(99)01513-3.
   PubMedGoogle Scholar
• O’Callaghan CA. Molecular basis of human natural killer cell recognition of HLA-E (human leucocyte antigen-E) and its relevance to clearance of pathogen-infected and tumour cells. Clin Sci. (Lond). 2000;99(1):9–17. doi:10.1042/CS19990334.
   PubMed Web of Science ®Google Scholar
• Repp AC, Mayhew ES, Apte S, et al. Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells. J Immunol. 2000;165(2):710–715. doi:10.4049/jimmunol.165.2.710.
   PubMed Web of Science ®Google Scholar
• Apte RS, Mayhew E, Niederkorn JY. Local inhibition of natural killer cell activity promotes the progressive growth of intraocular tumors. Invest Ophthalmol Vis Sci. 1997;38(6):1277–1282.
   PubMed Web of Science ®Google Scholar
• Apte RS, Sinha D, Mayhew E, et al. Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol. 1998;160(12):5693–5696.
   PubMed Web of Science ®Google Scholar